Drugs / Selatogrel
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07615868 | Jun → Oct 2026 expected | coronary artery disorder | Viatris Innovation GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT07133191 | Oct → Nov 2025 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04557280 | Nov → Dec 2020 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04406896 | Jul → Oct 2020 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03814200 | Jan → Feb 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03593278 | Jul → Aug 2018 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03430661 | Jan 2018 → May 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01954615 | Oct 2011 → Mar 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03487445 | Jul → Nov 2018 | acute myocardial infarction | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03384966 | Jan → Aug 2018 | coronary atherosclerosis | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04957719 | Aug 2021 → Dec 2026 expected | acute myocardial infarction | Viatris Innovation GmbH | Enrolling by invitation | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selatogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03384966 ↗ |
| Known as | ACT-246475 | “Randomized Trial to Assess the Pharmacokinetics, the Pharmacodynamics, and the Tolerability of a Single 16 mg Dose of Selatogrel (ACT-246475) in Chinese Adults With Chronic...” NCT07615868 ↗6“Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475” NCT03593278 ↗ “pharmacokinetics of selatogrel (ACT-246475).” NCT04406896 ↗ |
| Action | Inhibit | “Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration.” NCT03384966 ↗1“Purinergic receptor P2Y12 antagonist” CHEMBL4297589 ↗ |
| Modality | Small molecule | — CHEMBL4297589 ↗ |
| Route | Oral | “single, oral dose of ACT-246475” NCT01954615 ↗ |
| Target | P2RY12 | “Purinergic receptor P2Y12 antagonist” CHEMBL4297589 ↗ |